Reimbursed Care Access in Libya

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Libya’s domestic narcotics/psychotropic legislation imposes criminal penalties for unauthorized importation, possession and trafficking of psychotropic substances; national implementing language follows international scheduling obligations. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is internationally scheduled and Libya’s drug control framework criminalizes unauthorized handling of scheduled psychotropic compounds. # #

Esketamine (S‑ketamine; e.g., Spravato) is an internationally‑licensed pharmaceutical for treatment‑resistant depression in jurisdictions that have approved it, but there is no public record of a Libyan national marketing authorisation or a national reimbursement pathway for esketamine. Ketamine itself is used in Libyan clinical practice as an anaesthetic, however the novel intranasal esketamine product requires national regulatory authorisation and post‑licence funding decisions before it could be reimbursed — neither of which appear to be documented in Libyan public sources. For context, esketamine was approved in other jurisdictions (e.g., FDA approval 2019) as a prescription product for TRD, but such approvals do not imply availability or reimbursement in Libya. # #

Ketamine is an established anaesthetic and analgesic used in Libyan clinical practice (hospital anaesthesia and emergency care) and appears in clinical reports and local medical literature describing its use in perioperative and emergency settings in Libya. Use as an anaesthetic conforms with international essential‑medicine guidance: ketamine is listed on the World Health Organization Model List of Essential Medicines as an injectable anaesthetic. # #

Regulatory & reimbursement context: Libya’s national drug control law criminalizes unauthorized importation, possession or trafficking of controlled psychotropic substances and provides the statutory framework under which medical use is permitted through authorised healthcare channels; however Libya does not publish a clearly defined, national reimbursement schedule for novel psychiatric indications of ketamine (e.g., intranasal/off‑label use for treatment‑resistant depression). In practice, ketamine is available and used in hospitals for anaesthesia and some off‑label uses (reported in regional clinical practice and academic articles), but there is no documented nationwide public insurance program that reimburses ketamine for psychedelic‑assisted psychiatric therapy in Libya. Public vs private nuance: because Libya’s health financing is fragmented and heavily reliant on public hospitals with variable supplies and out‑of‑pocket private care, any provision of ketamine outside standard anaesthesia is likely to be arranged on an ad‑hoc, facility level rather than via a national reimbursement policy. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT is listed as a Schedule I substance at the UN level and Libya’s domestic law criminalizes unauthorized handling of scheduled psychotropic agents. Any ceremonial preparations (e.g., ayahuasca) that contain DMT would likewise be prohibited absent an explicit research or regulatory exemption. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Libya’s domestic framework does not provide a pathway for approved therapeutic use of 5‑MeO‑DMT outside clinical trials. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public record of authorised medical or traditional exemptions for ibogaine in Libya. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Although ayahuasca as a plant brew is not enumerated in international schedules, its primary psychoactive constituent (DMT) is scheduled and Libya’s domestic law does not provide exemptions for ceremonial use. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (the active alkaloid in peyote and other cacti) is covered by international scheduling and Libya enforces strict domestic controls consistent with that framework. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The phenethylamine series (2C compounds and related analogues) are covered by international controls or national analogue provisions; Libya’s law criminalizes unauthorised manufacture, import, possession and trafficking. # #